Product image of Ioflupan (123i) Rotop (Ioflupane (123i)) supplied by GNH India

Ioflupan (123i) Rotop

Active Ingredient:
Ioflupane (123i)
Origin:
EU

Ioflupan (123i) Rotop (Ioflupane (123i))

Ioflupane, the active ingredient in Ioflupan (123i) Rotop, is a radiopharmaceutical presented as an injection for intravenous use. It is employed to evaluate Parkinsonian syndromes and to aid the differential diagnosis of movement disorders in adult patients.

GNH India supplies Ioflupan (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Rotop Radiopharmacy Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ioflupan (123i) Rotop is used in the dopaminergic imaging pathway to assess neurological disorders.

  • Parkinsonian syndromes: visualizes loss of presynaptic dopamine neurons to support diagnosis.
  • Atypical parkinsonian disorders: helps distinguish conditions such as multiple system atrophy or progressive supranuclear palsy from idiopathic Parkinson disease.
  • Other movement disorders: provides functional imaging to evaluate tremor, dystonia, or drug‑induced parkinsonism.

How It Works

  • Ioflupane binds with high affinity to presynaptic dopamine transporters (DAT) located on nigrostriatal neurons. After intravenous administration, the radiolabelled compound is taken up by intact dopaminergic terminals, allowing single‑photon emission computed tomography (SPECT) to map DAT density and assess neuronal integrity in the striatum.

Side Effects

Ioflupan (123i) Rotop may cause adverse reactions related to the injection and its radioactive nature.

Common Side Effects

  • Injection site pain or erythema.
  • Mild nausea or vomiting.
  • Transient headache.
  • Flushing or warmth sensation.
  • Temporary mild hypotension.
  • Dizziness.

Serious or Rare Side Effects

  • Severe allergic reaction (anaphylaxis).
  • Significant hypotension requiring medical intervention.
  • Radiation‑induced skin injury at the injection site.
  • Seizure activity.
  • Pulmonary hypertension.
  • Cardiac arrhythmia.

Precautions & Warnings

Before using Ioflupan (123i) Rotop, consider the following safety measures.

  • Pregnancy: unknown; avoid unless clearly needed.
  • Breastfeeding: unknown; weigh potential risks before administration.
  • Renal impairment: assess renal function as clearance may be affected.
  • Concomitant dopamine‑affecting drugs: monitor for altered imaging results.
  • Radiation safety: follow local regulations for handling and disposal of radioactive material.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ioflupan (123i) Rotop can interact with other agents that influence dopamine pathways or hemodynamics.

Major Interactions (Avoid)

  • MAO inhibitors: may modify DAT binding and imaging accuracy.
  • Antipsychotics (D2 antagonists): can block tracer uptake, compromising results.
  • Dopamine‑transporter blockers (e.g., cocaine, methylphenidate): reduce tracer accumulation.

Moderate Interactions (Monitor Closely)

  • Antihypertensive drugs: may exacerbate transient hypotension after injection.
  • Sedatives: could mask patient discomfort during the procedure.
  • Contrast agents used in other imaging studies: may interfere with SPECT interpretation.

Frequently Asked Questions

Ioflupan (123i) Rotop is a radiopharmaceutical used to visualize presynaptic dopamine transporters in the brain. It assists clinicians in evaluating Parkinsonian syndromes and distinguishing them from other movement disorders through SPECT imaging.

Ioflupane binds selectively to dopamine transporters on intact dopaminergic neurons. After intravenous injection, the radiolabelled compound accumulates in regions with functional transporters, allowing SPECT scanners to generate images that reflect neuronal integrity.

The dose of Ioflupan (123i) Rotop is determined by the prescribing physician based on the imaging protocol, patient weight, and regulatory guidelines. Specific dosing regimens are not publicly disclosed and must be set by a qualified healthcare professional.

Safety data for Ioflupan (123i) Rotop in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risks, and clinicians should discuss individual circumstances with the patient.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ioflupan (Ioflupane) is a widely used DAT tracer with high affinity and favorable imaging characteristics. Compared with alternatives such as ^123I‑FP‑CIT, it offers comparable sensitivity for detecting dopaminergic deficits, but selection often depends on local regulatory approval, imaging equipment, and institutional experience.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Follow all radiopharmaceutical handling guidelines to maintain stability and safety.

Ioflupan (123i) Rotop is administered as a single intravenous injection under controlled conditions. After administration, patients typically wait for a prescribed uptake period before undergoing SPECT imaging to capture the tracer distribution.

Serious risks include severe allergic reactions (anaphylaxis), significant hypotension, radiation‑induced skin injury, seizures, and cardiac arrhythmias. These events are rare but require immediate medical attention if they occur.

Patients with known hypersensitivity to Ioflupane or any component of the formulation, those who are pregnant or breastfeeding without a clear clinical indication, and individuals unable to tolerate intravenous injections should not receive the product.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ioflupane (123i)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT